The Science of the Endocannabinoid System and Neurodivergence: What the Research Shows

In our previous post, we looked at the lived experience of sensory overload in Aotearoa: why the supermarket can feel like a battlefield and how the modern office often fails the neurodivergent brain. But for many people, especially those who prefer to see the data before making a health decision, the question remains: why?

Why do some brains process sound, light, and touch so differently? And why are researchers increasingly looking at the endocannabinoid system (ECS) as a potential key to understanding these differences?

As medicinal cannabis becomes a more common part of the clinical landscape in New Zealand, it is important to look past the anecdotes and dive into the emerging science. While we are still in the early stages of discovery, the research being conducted globally is starting to paint a fascinating picture of how our internal regulatory systems might influence neurodivergent traits.

Understanding the Endocannabinoid System (ECS) and Homeostasis

Before looking at the link to neurodivergence, it helps to understand what the endocannabinoid system actually is. Every human has one, regardless of whether they have ever used medicinal cannabis.

Think of the ECS as a master conductor for your body’s nervous system. Its main job is to keep everything in balance. It helps regulate sleep, mood, memory, appetite, and how we respond to stress.

The system is made up of three main parts:

1. Endocannabinoids: These are molecules made by your own body. The two most well-known are anandamide and 2-AG.
2. Receptors: These sit on the surface of cells throughout your body, waiting for endocannabinoids to “dock” with them. The two primary types are CB1 (mostly found in the brain and central nervous system) and CB2 (mostly found in the immune system).
3. Enzymes: These break down the endocannabinoids once they have fulfilled their purpose.

In a neurotypical system, this conductor ensures that the “volume” of your nervous system is set just right. In a neurodivergent system, researchers are finding evidence that this conductor might be working from a different score.

The Biological Link Between the ECS, Autism and ADHD

Researchers have been looking at the biology behind conditions like autism and ADHD for a long time. More recently, a growing number of studies suggest the endocannabinoid system may play a part in how these conditions show up.

One interesting finding involves a molecule your body makes called anandamide, sometimes nicknamed the “bliss molecule”. It plays a role in how we experience social connection and manage our emotions. A study published in Molecular Autism found that children with autism had noticeably lower levels of anandamide compared to neurotypical children.

This has led some researchers to ask: what if the body isn’t making enough of these molecules, or the receptors aren’t picking up the signals properly? If that’s the case, the nervous system could end up out of balance, which may contribute to some of the experiences many neurodivergent people know well, like heightened anxiety, difficulty reading social situations, and trouble sleeping.

How our internal biology handles sensory input

In our first post, we discussed the “noisy signals” in a neurodivergent brain: the way the brain struggles to filter out background noise. Researchers are now looking at how the ECS might be involved in this filtering process.

CB1 receptors are found in high numbers in the parts of the brain that handle sensory information and emotional responses. Studies suggest the ECS acts like a buffer. When there’s too much noise in the system, it helps to turn the volume down.

When the ECS isn’t working as well as it could, that buffer may be weaker. This could help explain why a sound that barely registers for one person can feel overwhelming for someone else. The brain’s ability to turn down the incoming signal just isn’t doing its job as effectively. By studying how cannabinoid compounds interact with these receptors, scientists are hoping to better understand how this filtering process works and what happens when it doesn’t.

What the research says about anxiety and social interaction

One of the most researched areas regarding medicinal cannabis and neurodivergence is its impact on anxiety and social communication. For many neurodivergent adults, the anxiety of “masking,” which is trying to appear neurotypical in social situations, can be exhausting.

One early study looked at children and young people with autism who were dealing with serious behavioural challenges. After a care plan involving CBD rich medicinal cannabis was introduced, the researchers noted that a number of participants showed improvements in social communication and a reduction in anxiety related behaviours.

It’s worth being clear about what this research is and isn’t saying. Nobody is suggesting that medicinal cannabis “fixes” neurodivergence. What researchers are exploring is whether it might help with some of the day to day challenges, like anxiety or difficulty switching off, that can make life harder. There’s still a lot more work to be done before any firm conclusions can be drawn.

Sleep, routine, and your internal clock

Sleep is another area where the neurodivergent experience often differs from the neurotypical one. Many people with ADHD or autism struggle with a delayed sleep-wake cycle or find it incredibly difficult to “switch off” at night.

The ECS plays a big part in regulating our body clock, the internal system that tells us when to sleep and when to wake up. Early research suggests that CBD may interact with the receptors involved in this process, though the exact way it works is still being studied. Some individual case reports have been encouraging, but larger studies are needed before we can say anything definitive.

For a neurodivergent person, better sleep isn’t just about feeling rested. It’s about having more in the tank to deal with the sensory demands of the next day. That’s one of the reasons researchers are so interested in how the ECS and sleep are connected, and why it remains such an active area of study.

Why we focus on neutral reporting

When reading about medicinal cannabis research, it is vital to distinguish between “observed outcomes” and “guaranteed results”. At the Cannabis Clinic, we follow the science closely, and the science tells us that every person’s endocannabinoid system is unique.

What works for one patient might not work for another. This is why the clinical pathway in New Zealand is so important. We do not look at medicinal cannabis as a generic wellness product, but as a doctor-guided treatment that must be carefully monitored.

Researchers are still figuring out the best balance of compounds like CBD and THC for different neurodivergent experiences. Most of the current research in this area focuses on products that are mainly CBD, because CBD doesn’t produce the “high” associated with THC and has generally been shown to be well tolerated.

The professional clinical landscape in New Zealand

In Aotearoa, we are fortunate to have a legal framework that prioritises patient safety and product quality. Any medicinal cannabis product prescribed by a doctor must meet strict Minimum Quality Standards. This ensures that patients are receiving a consistent, clean product, which is essential when you are trying to find a stable care plan.

If you’re a neurodivergent adult exploring whether medicinal cannabis could be part of your care plan, the process typically looks like this:

• A thorough consultation: Talking through how your daily life is affected, so the doctor can understand whether medicinal cannabis might be a useful addition to your broader care plan.
• Doctor-led guidance: If medicinal cannabis is considered appropriate, your doctor will work with you on a plan guided by the latest available research.
• Ongoing care: Regularly checking in to see how your system is responding and making adjustments as needed.

This professional oversight is what separates medicinal cannabis from products you might find elsewhere. It is a medical approach to a biological system.

Where is the research heading next?

We are currently in a very active era of ECS research. As the stigma around medicinal cannabis continues to fade, more universities and clinical institutions are getting the green light to conduct high-quality trials.

One area that’s getting a lot of attention is the connection between the gut and the brain. Many neurodivergent people also experience digestive issues, and the gut contains a large number of CB2 receptors. Researchers are starting to explore whether what happens in the gut might influence how the brain processes things like mood and stress.

As more research is done here in New Zealand and around the world, our understanding will keep growing. The hope is that we’re moving toward a future where care is built around the individual, and where a person’s unique brain and body are the starting point for their plan.

References

1. Karhson, D. S., et al. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9(1), 18. https://doi.org/10.1186/s13229-018-0203-y
2. Hughes, V. (2024). Autism brains have noisy signals, imaging study finds. The Transmitter. https://www.thetransmitter.org/spectrum/autism-brains-have-noisy-signals-imaging-study-finds/
3. Aran, A., et al. (2018). Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems. Journal of Autism and Developmental Disorders, 49(3), 1284-1288. https://doi.org/10.1007/s10803-018-3808-2
4. Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports, 19(11), 23. https://doi.org/10.1007/s11920-017-0775-9
5. Ma, L., Platnick, S., & Platnick, H. (2022). Cannabidiol in treatment of autism spectrum disorder: A case study. Cureus, 14(8), e28442. https://doi.org/10.7759/cureus.28442
6. Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2(1), 139-154. https://doi.org/10.1089/can.2016.0034
7. Sharkey, K. A., & Wiley, J. W. (2016). The Role of the Endocannabinoid System in the Control of Gastrointestinal Motility and Inflammation. Gastroenterology, 151(2), 252-266. https://doi.org/10.1053/j.gastro.2016.04.015